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participation. Patients with cardiogenic shock and acute MI were excluded.
Results: 57 patients (27 BMS, 30 DES) were enrolled in 4 centers in 3 European
countries. There was no distal embolization in both groups. MACEs rates at 1 and 6
months were resp. 3.7% and 11.1% in BMS group, and 3.3% and 10,0% in DES
group. The patients in the DES group, found to be more complex, performed well
compared to BMS group, although there was no statistical difference.
Conclusions: MACE at 12 months will be presented, as well as lumen loss and
angiographic results at 6 months, and OCT followup at 6 months.Table. Angioscopic ﬁndings in G2-DES
Stable plaque
BES
(n¼6)
EES
(n¼11)
E-ZES
(n¼7)
R-ZES
(n¼7)
p-value
Good NSC (%) 16.7 45.5 100.0 28.6 0.01
Prevalence of YP
(%)
16.7 18.2 0.0 0.0 0.43
Vulnerable plaque
BES
(n¼8)
EES
(n¼8)
E-ZES
(n¼5)
R-ZES
(n¼11)
p-value
Good NSC (%) 25.0 12.5 100.0 54.5 0.01
Prevalence of YP
(%)
85.7 0.0 0.0 9.1 <0.0001
BES; biolimus-eluting stent, EES; everolimus-eluting stent, E-ZES; Endeavor zotarolimus-eluting
stent, R-ZES; Resolute zotarolimus-eluting stentStents - Drug-eluting: Novel Metallic DES
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Background: The Svelte (New Providence, NJ) sirolimus-eluting coronary stent
utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel
Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon
control bands (BCBs) afﬁxed to a 0.014 integrated wire with shapeable tip. The IDS
is low-proﬁle and speciﬁcally designed for use with the trans-radial approach (TRI),
‘slender’ PCI and direct stenting. The DIRECT I First-In-Man study (n¼30) reports
2.7% stent volume obstruction (via IVUS) at 6-months with 0% clinically-driven
MACE through 24-months. All events and imaging were reviewed and adjudicated by
an independent core lab and DSMB.
Methods: 159 patients with symptomatic ischemic heart disease due to de novo
stenotic lesions in arteries with RVD 2.5mm – 3.5mm and lesion length < 20 mm
were prospectively randomized (2:1 Svelte IDS : Medtronic Resolute Integrity) at 18
sites in Europe. Clinical and angiographic follow-up was scheduled at 6-months to
assess TVF and LL as well as multiple secondary endpoints, with clincial follow-up
continuing through 5-years. Stent evaluation post-procedure and at 6-months via OCT
was also performed in 30 patients. All events and imaging were reviewed and adju-
dicated by an independent core lab and DSMB.
Results: Study enrolment completed November 2013 (n¼106 Svelte IDS arm, n¼51
Medtronic Resolute Integrity); 6-month data on all available patients is expected
May 2014. Procedural, 30-day and 6-month clinical and angiographic data on all
patients, along with OCT image analysis (n¼30), will be presented. Comparative
data for time and cost savings, including TRI vs. femoral approach, procedure and
device time, adjunctive product and contrast use, and radiation exposure, will be
reported.
Conclusions: A review of the Svelte DES platform and available procedural,
30-day and 6-month angiographic, clinical and OCT outcomes from the study will
be reported. These data provide ﬁrst insights into the safety, efﬁcacy and proce-
dural efﬁciencies, as well as time and cost savings, of this unique DES IDS system
compared with a prospective, matched control group utilizing a conventional DES
system.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-600
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Background: The second generation drug-eluting stents (G2-DES) have been
implanted safely at culprit lesions not only of stable angina pectoris but also of acute
coronary syndrome. The aim of this study was to angioscopically characterize vascular
response after implantation of various G2-DES and to compare healing processes
between stable and vulnerable plaques.
Methods: Enrolled were consecutive 64 patients who were successfully implanted
with various G2-DES. Five patients were withdrawn from further analysis be-
cause of death or stroke. Coronary angiography at one year after stenting detected
in-stent restenosis in 6 patients, who were excluded from further analysis. Sub-
sequently, coronary angioscopy was performed in 63 lesions (32 vulnerable and
31 stable plaques) of 53 patients, revealing the in-stent appearance of each G2-
DES, that is, [1] neointimal stent coverage (NSC, good/poor), [2] presence of
thrombus (presence/absence), and [3] presence of yellow plaques (YP, presence/
absence).
Results: In-stent thrombus was detected at only 1 vulnerable plaque implanted with
BES. As shown in table, in both vulnerable and stable plaques, E-ZES was better
covered with neointima than other G2-DES. In stable plaques, no signiﬁcant differ-
ences were found in YP prevalence among G2-DES. In vulnerable plaques, however,
prevalence of YP was signiﬁcantly higher in BES than in another G2-DES.Conclusions: Vulnerable plaques implanted with BES remained yellowish and
thrombogenic even at one year after stenting, suggesting the distinct vascular response
after BES implantation at vulnerable plaques.
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Background: Nevertheless the promising results of 2nd generation DES, recent
ﬁndings suggest hypersensitivity reactions caused by the durable polymer coatings
leading to chronic inﬂammation and possibly to late stent strut malapposition.
Therefore new DES generations with improved biocompatibility and biodegradable
polymers were introduced.
Methods: The registry aims to compare optical coherence tomography (OCT) based
stent coverage at three, six and nine-months follow-up after PCI by 3rd generation
Orsiro Hybrid sirolimus-eluting stents with biodegradable polymer (O-SES, Bio-
tronik) and widely used 2nd generation zotarolimus-eluting stents with durable
polymer (ZES, Endeavor Resolute and Resolute Integrity, Medtronic
Vascular). A total of 80 patients received implantation of O-SES (n¼34) and ZES
(n¼46). Clinical driven OCT-analysis was performed at three, six or nine-months
follow-up.nts - Drug-eluting: Novel Metallic DES B175
